Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Vlado Perkovic; Rajiv Agarwal; Paola Fioretto; Brenda R. Hemmelgarn; Adeera Levin; Merlin C. Thomas; Christoph Wanner; Bertram L. Kasiske; David C. Wheeler; Per Henrik Groop; George L. Bakris; Mark E. Cooper; Dong Wan Chae; Michael H. Davidson; Ian H. de Boer; Dick de Zeeuw; Alessia Fornoni; Luigi Gnudi; Charles A. Herzog; Adriana M. Hung; Tazeen Hasan Jafar; Meg Jardine; Vivekanand Jha; Linong Ji; Steven E. Kahn; Robyn G. Langham; Edgar V. Lerma; Ronald C.W. Ma; Hirofumi Makino; Michel Marre; Michael Mauer; Kaj Metsärinne; Robert G. Nelson; Roberto Pecoits-Filho; Carol A. Pollock; Mohan Rajapurkar; Peter Rossing; Ivan Rychlík; Kumar Sharma; Robert C. Stanton; Vladimír Tesař; Ilkka Tikkanen; Charlie R.V. Tomson; Robert D. Toto; Yusuke Tsukamoto; Katherine R. Tuttle; Takashi Wada; Winfred W. Williams; Hong Zhang; Sophia Zoungas

doi:10.1016/j.kint.2016.09.010

Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R. Hemmelgarn, Adeera Levin, Merlin C. Thomas, Christoph Wanner, Bertram L. Kasiske, David C. Wheeler, Per Henrik Groop, George L. Bakris, Mark E. Cooper, Dong Wan Chae, Michael H. Davidson, Ian H. de Boer, Dick de Zeeuw, Alessia Fornoni, Luigi Gnudi, Charles A. Herzog, Adriana M. HungTazeen Hasan Jafar, Meg Jardine, Vivekanand Jha, Linong Ji, Steven E. Kahn, Robyn G. Langham, Edgar V. Lerma, Ronald C.W. Ma, Hirofumi Makino, Michel Marre, Michael Mauer, Kaj Metsärinne, Robert G. Nelson, Roberto Pecoits-Filho, Carol A. Pollock, Mohan Rajapurkar, Peter Rossing, Ivan Rychlík, Kumar Sharma, Robert C. Stanton, Vladimír Tesař, Ilkka Tikkanen, Charlie R.V. Tomson, Robert D. Toto, Yusuke Tsukamoto, Katherine R. Tuttle, Takashi Wada, Winfred W. Williams, Hong Zhang, Sophia Zoungas

Medical School

Research output: Contribution to journal › Article › peer-review

96 Citations (Scopus)

Abstract

The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.

Original language	English
Pages (from-to)	1175-1183
Number of pages	9
Journal	Kidney International
Volume	90
Issue number	6
DOIs	https://doi.org/10.1016/j.kint.2016.09.010
Publication status	Published - Dec 1 2016

Keywords

antidiabetic agents
cardiovascular disease
chronic kidney disease
diabetes
glycemic control
renoprotection

ASJC Scopus subject areas

Nephrology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.kint.2016.09.010

Cite this

Perkovic, V., Agarwal, R., Fioretto, P., Hemmelgarn, B. R., Levin, A., Thomas, M. C., Wanner, C., Kasiske, B. L., Wheeler, D. C., Groop, P. H., Bakris, G. L., Cooper, M. E., Chae, D. W., Davidson, M. H., de Boer, I. H., de Zeeuw, D., Fornoni, A., Gnudi, L., Herzog, C. A., ... Zoungas, S. (2016). Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney International, 90(6), 1175-1183. https://doi.org/10.1016/j.kint.2016.09.010

Perkovic, V, Agarwal, R, Fioretto, P, Hemmelgarn, BR, Levin, A, Thomas, MC, Wanner, C, Kasiske, BL, Wheeler, DC, Groop, PH, Bakris, GL, Cooper, ME, Chae, DW, Davidson, MH, de Boer, IH, de Zeeuw, D, Fornoni, A, Gnudi, L, Herzog, CA, Hung, AM, Jafar, TH, Jardine, M, Jha, V, Ji, L, Kahn, SE, Langham, RG, Lerma, EV, Ma, RCW, Makino, H, Marre, M, Mauer, M, Metsärinne, K, Nelson, RG, Pecoits-Filho, R, Pollock, CA, Rajapurkar, M, Rossing, P, Rychlík, I, Sharma, K, Stanton, RC, Tesař, V, Tikkanen, I, Tomson, CRV, Toto, RD, Tsukamoto, Y, Tuttle, KR, Wada, T, Williams, WW, Zhang, H & Zoungas, S 2016, 'Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference', Kidney International, vol. 90, no. 6, pp. 1175-1183. https://doi.org/10.1016/j.kint.2016.09.010

@article{cc315beae1974e288691fed573116f20,

title = "Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference",

abstract = "The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.",

keywords = "antidiabetic agents, cardiovascular disease, chronic kidney disease, diabetes, glycemic control, renoprotection",

author = "Vlado Perkovic and Rajiv Agarwal and Paola Fioretto and Hemmelgarn, {Brenda R.} and Adeera Levin and Thomas, {Merlin C.} and Christoph Wanner and Kasiske, {Bertram L.} and Wheeler, {David C.} and Groop, {Per Henrik} and Bakris, {George L.} and Cooper, {Mark E.} and Chae, {Dong Wan} and Davidson, {Michael H.} and {de Boer}, {Ian H.} and {de Zeeuw}, Dick and Alessia Fornoni and Luigi Gnudi and Herzog, {Charles A.} and Hung, {Adriana M.} and Jafar, {Tazeen Hasan} and Meg Jardine and Vivekanand Jha and Linong Ji and Kahn, {Steven E.} and Langham, {Robyn G.} and Lerma, {Edgar V.} and Ma, {Ronald C.W.} and Hirofumi Makino and Michel Marre and Michael Mauer and Kaj Mets{\"a}rinne and Nelson, {Robert G.} and Roberto Pecoits-Filho and Pollock, {Carol A.} and Mohan Rajapurkar and Peter Rossing and Ivan Rychl{\'i}k and Kumar Sharma and Stanton, {Robert C.} and Vladim{\'i}r Tesa{\v r} and Ilkka Tikkanen and Tomson, {Charlie R.V.} and Toto, {Robert D.} and Yusuke Tsukamoto and Tuttle, {Katherine R.} and Takashi Wada and Williams, {Winfred W.} and Hong Zhang and Sophia Zoungas",

note = "Funding Information: The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from AbbVie, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Janssen, Merck, Roche, Takeda, and ZS Pharma. Funding Information: VP declared having received consultancy fees from Abbvie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Novo Nordisk, Pharmalink, Relypsa, and Servier; speaker honoraria from International Diabetes Federation, Pfizer, and Sanofi; and research support from Abbvie, Jannsen and Pfizer. All monies were given to The George Institute. RA declared having received consultancy fees from Abbvie, Bayer, Celgene, Daiichi Sankyo, Janssen, and Takeda, and research support from the National Heart, Lung, and Blood Institute and Veterans Administration. MCT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly, and speaker honoraria from AstraZeneca, BGP, Boehringer Ingelheim, Eli Lilly, Merck Sharpe & Dohme, Novartis, and Servier. CW declared having received consultancy fees from Boehringer Ingelheim and Janssen and speaker honoraria from Boehringer Ingelheim. DCW declared having received consultancy fees from Akebia, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Otsuka, UCB Celltech, and Vifor; speaker honoraria from Amgen, Fresenius, Janssen, Vifor, and ZS Pharma; and research support from British Heart Foundation, Healthcare Quality Improvement Partnership, Kidney Research UK, National Institute for Health Research, and Australian National Health & Medical Research Council. All the other authors declared no competing interests. Publisher Copyright: {\textcopyright} 2016 International Society of Nephrology",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.kint.2016.09.010",

language = "English",

volume = "90",

pages = "1175--1183",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Management of patients with diabetes and CKD: conclusions from a “Kidney Disease

T2 - Improving Global Outcomes” (KDIGO) Controversies Conference

AU - Perkovic, Vlado

AU - Agarwal, Rajiv

AU - Fioretto, Paola

AU - Hemmelgarn, Brenda R.

AU - Levin, Adeera

AU - Thomas, Merlin C.

AU - Wanner, Christoph

AU - Kasiske, Bertram L.

AU - Wheeler, David C.

AU - Groop, Per Henrik

AU - Bakris, George L.

AU - Cooper, Mark E.

AU - Chae, Dong Wan

AU - Davidson, Michael H.

AU - de Boer, Ian H.

AU - de Zeeuw, Dick

AU - Fornoni, Alessia

AU - Gnudi, Luigi

AU - Herzog, Charles A.

AU - Hung, Adriana M.

AU - Jafar, Tazeen Hasan

AU - Jardine, Meg

AU - Jha, Vivekanand

AU - Ji, Linong

AU - Kahn, Steven E.

AU - Langham, Robyn G.

AU - Lerma, Edgar V.

AU - Ma, Ronald C.W.

AU - Makino, Hirofumi

AU - Marre, Michel

AU - Mauer, Michael

AU - Metsärinne, Kaj

AU - Nelson, Robert G.

AU - Pecoits-Filho, Roberto

AU - Pollock, Carol A.

AU - Rajapurkar, Mohan

AU - Rossing, Peter

AU - Rychlík, Ivan

AU - Sharma, Kumar

AU - Stanton, Robert C.

AU - Tesař, Vladimír

AU - Tikkanen, Ilkka

AU - Tomson, Charlie R.V.

AU - Toto, Robert D.

AU - Tsukamoto, Yusuke

AU - Tuttle, Katherine R.

AU - Wada, Takashi

AU - Williams, Winfred W.

AU - Zhang, Hong

AU - Zoungas, Sophia

N1 - Funding Information: The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from AbbVie, AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, Fresenius Medical Care, Janssen, Merck, Roche, Takeda, and ZS Pharma. Funding Information: VP declared having received consultancy fees from Abbvie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Novo Nordisk, Pharmalink, Relypsa, and Servier; speaker honoraria from International Diabetes Federation, Pfizer, and Sanofi; and research support from Abbvie, Jannsen and Pfizer. All monies were given to The George Institute. RA declared having received consultancy fees from Abbvie, Bayer, Celgene, Daiichi Sankyo, Janssen, and Takeda, and research support from the National Heart, Lung, and Blood Institute and Veterans Administration. MCT declared having received consultancy fees from AstraZeneca, Boehringer Ingelheim, and Eli Lilly, and speaker honoraria from AstraZeneca, BGP, Boehringer Ingelheim, Eli Lilly, Merck Sharpe & Dohme, Novartis, and Servier. CW declared having received consultancy fees from Boehringer Ingelheim and Janssen and speaker honoraria from Boehringer Ingelheim. DCW declared having received consultancy fees from Akebia, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Otsuka, UCB Celltech, and Vifor; speaker honoraria from Amgen, Fresenius, Janssen, Vifor, and ZS Pharma; and research support from British Heart Foundation, Healthcare Quality Improvement Partnership, Kidney Research UK, National Institute for Health Research, and Australian National Health & Medical Research Council. All the other authors declared no competing interests. Publisher Copyright: © 2016 International Society of Nephrology

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.

AB - The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.

KW - antidiabetic agents

KW - cardiovascular disease

KW - chronic kidney disease

KW - diabetes

KW - glycemic control

KW - renoprotection

UR - http://www.scopus.com/inward/record.url?scp=84997241559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997241559&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2016.09.010

DO - 10.1016/j.kint.2016.09.010

M3 - Article

C2 - 27884312

AN - SCOPUS:84997241559

SN - 0085-2538

VL - 90

SP - 1175

EP - 1183

JO - Kidney International

JF - Kidney International

IS - 6

ER -